UNSPSC 51172705: Atropine/hyoscyamine/phenazopyridine/scopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU209. This VA Drug Class (GU209) classifies this compound as belonging to the group ANTISPASMODICS, URINARY, OTHER.

UNSPSC 51172705 Atropine/hyoscyamine/phenazopyridine/scopolamine is a Commodity code under which state and local governments procure branded and generic pharmaceuticals as components of broader drug-testing, pharmacy benefit, and multi-source generic procurement programs. The code sees activity primarily from county corrections and supervision departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state public-sector networks. Work being solicited includes specimen-collection and drug-testing services that incorporate pharmaceutical screening and confirmation methodologies, direct-to-manufacturer prescription programs seeking to bypass traditional pharmacy benefit manager and wholesaler channels, and generic pharmaceutical supply agreements negotiated through multi-state cooperative purchasing vehicles.

Recent activity concentrates in Texas, where Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a due date of July 23, 2026 and an estimated contract value of $600,000 over two years with optional renewals, and where the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Multi-state cooperative purchasing also drives activity under the code: the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 with proposals due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with contracts effective July 1, 2026.